Spots Global Cancer Trial Database for chimeric antigen receptor t cell
Every month we try and update this database with for chimeric antigen receptor t cell cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma | NCT04706936 | Relapsed or Ref... | anti-BCMA CAR-T Cyclophosphamid Fludarabine | 18 Years - 75 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| Study of Sequential CAR-T Cell Treating Leukemia Children | NCT04340154 | Acute Lymphobla... Acute Lymphobla... Refractory Acut... | chimeric antige... | 0 Years - 18 Years | Beijing Boren Hospital | |
| Safety and Efficiency Study of BCMA-PD1-CART Cells in Relapsed/Refractory Multiple Myeloma | NCT04162119 | Multiple Myelom... | BCMA-PD1-CART C... | 14 Years - 80 Years | Chinese PLA General Hospital | |
| Safety and Efficiency Study of BCMA-PD1-CART Cells in Relapsed/Refractory Multiple Myeloma | NCT04162119 | Multiple Myelom... | BCMA-PD1-CART C... | 14 Years - 80 Years | Chinese PLA General Hospital | |
| Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma | NCT04706936 | Relapsed or Ref... | anti-BCMA CAR-T Cyclophosphamid Fludarabine | 18 Years - 75 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| Study of Sequential CAR-T Cell Treating Leukemia Children | NCT04340154 | Acute Lymphobla... Acute Lymphobla... Refractory Acut... | chimeric antige... | 0 Years - 18 Years | Beijing Boren Hospital | |
| Clinical Study of Safety and Efficacy of Enhanced PSMA CAR- T in Refractory CRPC | NCT06228404 | Metastatic Cast... Castration-resi... | Enhanced autolo... | 18 Years - 75 Years | Shanghai Changzheng Hospital | |
| CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell Lymphoma | NCT04381741 | Diffuse Large B... | CD19-7×19 CAR-T... | 18 Years - 75 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma | NCT04272151 | Multiple Myelom... Multiple Myelom... Neoplasm, Plasm... | BCMA CAR-T cell... | 18 Years - 75 Years | Chongqing Precision Biotech Co., Ltd | |
| Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer. | NCT03267173 | Pancreatic Canc... CAR | Chimeric antige... | 18 Years - 65 Years | First Affiliated Hospital of Harbin Medical University | |
| CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell Lymphoma | NCT04381741 | Diffuse Large B... | CD19-7×19 CAR-T... | 18 Years - 75 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| Clinical Study of Safety and Efficacy of Enhanced PSMA CAR- T in Refractory CRPC | NCT06228404 | Metastatic Cast... Castration-resi... | Enhanced autolo... | 18 Years - 75 Years | Shanghai Changzheng Hospital | |
| The Mechanism of Enhancing the Anti-tumor Effects of CAR-T on PC by Gut Microbiota Regulation | NCT04203459 | Pancreatic Canc... Gut Microbiota CAR-T | 30 Years - 75 Years | First Affiliated Hospital of Harbin Medical University | ||
| BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma | NCT04271644 | Multiple Myelom... Neoplasm, Plasm... Multiple Myelom... | BCMA CAR-T cell... | 18 Years - 75 Years | Chongqing Precision Biotech Co., Ltd | |
| Safety and Efficacy of Loco-regional B7H3 IL-7Ra CAR T Cell in DIPG | NCT06221553 | DIPG Brain Tumo... Diffuse Intrins... | B7H3 specific C... | 1 Year - 18 Years | Chulalongkorn University | |
| Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant | NCT05984199 | Leukemia, Myelo... | VCAR33 | 18 Years - | Vor Biopharma | |
| BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma | NCT04271644 | Multiple Myelom... Neoplasm, Plasm... Multiple Myelom... | BCMA CAR-T cell... | 18 Years - 75 Years | Chongqing Precision Biotech Co., Ltd |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
